Brief: Outset Medical Q2 Net Income USD -18.541 Million

Outset Medical

06/08/2025 21:02

Overview

Outset Medical Q2 rev grows 15% yr/yr, driven by Tablo console sales

Operating expenses down 30%, contributing to reduced net loss

Co raises 2025 revenue guidance

Outlook

Outset raises 2025 revenue guidance to $122 mln-$126 mln

Company expects 2025 non-GAAP gross margin in high-30% range

Outset anticipates using less than $50 mln cash in 2025

Result Drivers

TABLO CONSOLE SALES - 25% increase in Tablo console revenue drove overall revenue growth, per CEO Leslie Trigg

CONSUMABLES GROWTH - 17% increase in consumable revenue contributed to recurring revenue growth

COST REDUCTION - Operating expenses declined nearly 30%, aiding in reduced net loss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$18.54 mln
Q2 Gross Margin
37.8%
Q2 Basic EPS
-$1.04
Q2 Gross Profit
$11.87 mln
Q2 Operating Expenses
$28.73 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Outset Medical Inc is $23.00, about 38.7% above its August 5 closing price of $14.10

Press Release: ID:nGNXbZNLRp

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)